About: Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 April 1991

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 1991 (uk) article scientifique publié en 1991 (fr) im April 1991 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'abril de 1991 (ast) scientific article published on 01 April 1991 (en)
publication date	wds:Q67985481-2FA04C68-3840-43D7-A645-DC49932A8E27
publication date	1991-04-01 00:00:00Z (xsd:dateTime)
rdfs:label	Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month (en) Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month (nl)
skos:prefLabel	Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month (en) Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month (nl)
name	Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month (en) Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month (nl)
title	wds:Q67985481-B035A084-F821-41AC-B4B2-DD3A02CC5C26
title	Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council (en)
page(s)	wds:Q67985481-BE7CA849-1092-449E-ABE3-C641DCB4E17E
page(s)	700-706
instance of	wds:Q67985481-933A5CC1-FE29-4148-80F9-DC7D4D912EF1
instance of	scholarly article
main subject	wds:Q67985481-0B73901B-C3F0-4B9D-B8F8-F06AE125A839 wds:Q67985481-3DBAC8B7-95EA-4CF7-B3F8-4EBBF15ECF08 wds:Q67985481-5F3F3FDA-8D68-491B-A5B8-F92DF304E4DB wds:Q67985481-897339EF-594B-43BD-8045-4C53A1C361D3 wds:Q67985481-CE2CF585-13A6-4C10-BA6C-A48B05A3223F
main subject	Heat shock protein family A (Hsp70) member 2 tuberculosis rifampicin isoniazid pulmonary tuberculosis
PubMed ID	wds:Q67985481-7A4B843D-38F6-4FD0-AA26-198C236E483B
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1901199
PubMed ID	1901199
published in	wds:Q67985481-33424360-384D-4D88-8B56-6BDFAFC0FAFD
published in	The American Review of Respiratory Disease
issue	wds:Q67985481-3C24C785-F867-454F-983E-D64FCB48C1A6
volume	wds:Q67985481-DA4F63D2-AF1E-45ED-9BA3-5397A3F15EA1
issue	4 Pt 1
volume	143
DOI	wds:Q67985481-22339671-281D-4C3C-9417-1E75DBBA8CD7
DOI	http://dx.doi.org/10.1164/AJRCCM/143.4_PT_1.700
DOI	10.1164/AJRCCM/143.4_PT_1.700
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q67985481
is cites work of	Biomarkers for tuberculosis disease activity, cure, and relapse Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study Current medical treatment for tuberculosis International standards for tuberculosis care Pharmacokinetic factors in the modern drug treatment of tuberculosis. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection Cytokine and Growth Factor Release by Alveolar Macrophages: Potential Biomarkers of Pulmonary Toxicity Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis Fully intermittent dosing with drugs for tuberculosis Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection Why is long-term therapy required to cure tuberculosis? Cerebrospinal fluid concentrations of antituberculosis agents in adults and children The chemotherapy of tuberculosis: past, present and future Assessment of the Efficacy of New Anti-Tuberculosis Drugs Treatment and prevention of multidrug-resistant tuberculosis Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Cost-effectiveness of novel first-line treatment regimens for tuberculosis. Tuberculosis in Africa: clinical presentation and management Tuberculosis control in resource-poor countries: alternative approaches in the era of HIV. Antituberculosis drug-induced hepatotoxicity in children Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens Avoidance and management of adverse reactions to antituberculosis drugs The chemotherapy of tuberculous meningitis in children and adults Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting Drug treatment of tuberculosis--1992 Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Current and potential treatment of tuberculosis Drug therapy in spinal tuberculosis [Tuberculous pneumothorax. Retrospective study of 23 cases in Tunisia] Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis Isoniazid-resistant tuberculosis: a cause for concern? Cost effectiveness of antituberculosis interventions. Pilot study of twice-weekly therapy for pulmonary tuberculosis in Taiwan Prospective randomized trial of six-month versus nine-month therapy for intestinal tuberculosis Intermittent versus daily therapy for treating tuberculosis in children Multidrug-resistant tuberculosis A follow up study on revised national tuberculosis control programme (rntcp): results from a single centre study JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committ Screening and treatment of immigrants and refugees to Canada for tuberculosis: Implications of the experience of Canada and other industrialized countries The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity? Tuberculosis chemotherapy: still a double-edged sword Pyrazinamide pharmacokinetics and efficacy in adults and children Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010 Drug-Resistant Tuberculosis: Challenges and Progress [Trends in tuberculosis treatment duration] Expression Profile of Markers of Apoptosis, Injury and Oxidative Stress in Human Lung Epithelium Cells-A5449 Receiving Chronic Exposure of Potential Anti-Tubercular Drug-trans-Cyclohexane-1, 4-Diamine Derivative-"9u". Antituberculous therapy and acute liver failure

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software